{'fraction_non_alphanumeric': 0.048034934497816595, 'fraction_numerical': 0.02292576419213974, 'mean_word_length': 5.55, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Metastatic urothelial cancer showing an efficacy by low‐dose cisplatin

A 69‐year‐old man who had developed multiple distant metastases on retrocaval lymph nodes after four courses of Methotraxate, Vinblastine, Adriamycin, Cisplatin (MVAC) chemotherapy was successfully treated by intravenous infusion of low‐dose cisplatin (CDDP) (10 mg/time, once per week) and oral administration of 600 mg/day 5′‐deoxy‐5‐fluorouridine (5′‐DFUR), a pro‐drug of 5‐FU, in an outpatient setting. A partial response (62% reduction rate) was confirmed by abdominal computed tomography (CT) scan after 7 months. Although the CDDP dosage had been reduced to 5 mg/week 1 year previously, the tumor was still reducing in size in November 2000. Combination therapy of 5′‐DFUR with low‐dose CDDP could become an option for advanced bladder cancer that compromises the patient’s quality of life, especially when used in an outpatient setting.